Results

eNauka >  Results >  Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study
Title: Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study
Authors: Dimopoulos, Meletios A.; Terpos, Evangelos; Boccadoro, Mario; Delimpasi, Sosana; Beksac, Meral; Katodritou, Eirini; Moreau, Philippe; Baldini, Luca; Symeonidis, Argiris; Bila, Jelena S.  ;
Oriol, Albert; Mateos, Maria-Victoria; Einsele, Hermann; Orfanidis, Ioannis; Kampfenkel, Tobias; Liu, Weiping; Kosh, Michele; NamPhuong, Tran; Carson, Robin; Sonneveld, Pieter;
Issue Date: 2022
Publication: Blood (64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Dec 10-13, 2022, New Orleans, LA)
ISSN: 0006-4971 Blood Search Idenfier
Type: Conference Paper
Collation: vol. 140 br. Suppl 1 str. 7272-7274
DOI: 10.1182/blood-2022-163483
WoS-ID: 000893230300126
URI: https://enauka.gov.rs/handle/123456789/802476
URL: https://ashpublications.org/blood/article/140/Supplement%201/7272/490351/Subcutaneous-Daratumumab-Plus-Pomalidomide-and
Metadata source: (Preuzeto iz Nasi u WoS)
M-category: 
Mp. category will be shown later

Altmetric
Dimensions
Unpaywall

Google ScholarTM

Items in eNauka are protected by copyright, with all rights reserved, unless otherwise indicated.